Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) as a first-line treatment for adults with inoperable or metastatic colorectal cancer with certain genetic features. These include high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) — both good indicators of impaired DNA repair, which increase the number of mutations in a tumor and the likelihood it will be seen as a threat by the immune system. An estimated 5%–15% of colorectal…
You must be logged in to read/download the full post.
The post Keytruda Approval Recommended in EU as First-line Therapy for Certain Colorectal Cancers appeared first on BioNewsFeeds.